This company listing is no longer active
Calliditas Therapeutics Valuation
Is LC8A undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of LC8A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: LC8A (€35) is trading below our estimate of fair value (€1874.76)
Significantly Below Fair Value: LC8A is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LC8A?
Key metric: As LC8A is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is LC8A's PS Ratio? | |
|---|---|
| PS Ratio | 6.8x |
| Sales | SEK 1.60b |
| Market Cap | SEK 126.85b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 80.7x |
| Enterprise Value/EBITDA | -353.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does LC8A's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.5x | ||
BAYN Bayer | 0.4x | 1.0% | €18.6b |
DMP Dermapharm Holding | 1.7x | 4.1% | €2.0b |
MRK Merck KGaA | 2.9x | 4.1% | €61.6b |
93M1 MPH Health Care | 0.9x | -60.2% | €105.3m |
LC8A Calliditas Therapeutics | 6.8x | 34.3% | €11.2b |
Price-To-Sales vs Peers: LC8A is expensive based on its Price-To-Sales Ratio (6.8x) compared to the peer average (1.6x).
Price to Sales Ratio vs Industry
How does LC8A's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 24 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 24 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: LC8A is expensive based on its Price-To-Sales Ratio (6.8x) compared to the European Pharmaceuticals industry average (3.8x).
Price to Sales Ratio vs Fair Ratio
What is LC8A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.8x |
| Fair PS Ratio | 14.2x |
Price-To-Sales vs Fair Ratio: LC8A is good value based on its Price-To-Sales Ratio (6.8x) compared to the estimated Fair Price-To-Sales Ratio (14.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.9b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$15.55
7D
1.6%
1Y
73.9%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
0.4%
1Y
-33.2%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.45
7D
1.1%
1Y
2.9%